Assessment of Aliskiren Hemifumarate and Amlodipine Besylate in combined Tablet Dosage form by Three Simple UV Spectrophotometric Methods

被引:1
作者
Sen, Ashim K. [1 ]
Sen, Dhanya B. [1 ]
Zanwar, Aarti S. [1 ]
Maheshwari, Rajesh A. [1 ]
Balaraman, R. [1 ]
机构
[1] Sumandeep Vidyapeeth Deemed Univ, Dept Pharm, Vadodara 391760, Gujarat, India
关键词
Aliskiren hemifumarate; amlodipine besylate; simultaneous equation; absorbance ratio; 1st derivative (zero-crossing) spectrophotometric methods; tablet formulation; HYDROCHLOROTHIAZIDE; VALIDATION;
D O I
10.9734/JPRI/2021/v33i39A32163
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: For a cardiovascular patient's blood pressure to be effectively controlled, more than one drug is required. When coupled with amlodipine besylate (AMLO), a calcium channel blocker, Aliskiren hemifumarate (ALI) is the 1st nonpeptide, low molecular mass, orally active transition state rennin inhibitor to efficaciously normalize blood pressure and cardiac ailments. Objective: Three innovative, easy, sensitive, exact, and accurate UV spectrophotometric approaches, including simultaneous equation method (SEM), absorbance ratio method (ARM) and 1st derivative (zero-crossing) spectroscopic approach (FDR), were created and authenticated by validation for synchronized estimation of ALI and AMLO in tablet formulation. Materials and Methods: The SEM was used to measure the absorbance of both medicines at 237 and 280 nm. ALI and AMLO were calculated using 237 and 271 nm, respectively, in the ARM. ALI and AMLO, on the other hand, used the FDR technique to transform UV spectra to first derivative spectra, with the first derivative signal captured at 237 and 254 nm, respectively. The wavelength interval (Delta lambda) was kept at 2 and the scaling factor was kept at 1 when transforming zero-order spectra using the first derivative approach. Validation of the proposed processes was done in compliance with the "International Conference on Harmonization" (ICH) recommendations. Results: SEM and ARM both showed a linear outcome in the range of 1-50 mu g/ml for ALI and AMLO. FDR, on the other hand, was shown to be more sensitive and linear between 0.5 and 50 mu g/ml for both medications. The results of the method validation parameters were within the allowed ranges of the ICH guidelines. Conclusion: The proposed procedures were shown to be relatively quick, sensitive, simple, and cost-effective, and can thus be used for scheduled quality control analysis of ALI and AMLO in the mixed tablet.
引用
收藏
页码:217 / 225
页数:9
相关论文
共 23 条
  • [1] [Anonymous], 2001, MERCK INDEX, V13th, P86
  • [2] [Anonymous], 2009, COMPLETE DRUG REFERE, VI, P1214
  • [3] [Anonymous], 2015, INT J PHARM PHARM SC
  • [4] [Anonymous], 2005, Validation of analytical procedures: Text and methodology Q2 (R1)
  • [5] [Anonymous], 2008, British Pharmacopoeia, VI, P137
  • [6] Spectrofluorimetric Determination of Aliskiren in Tablets and Spiked Human Plasma through Derivatization with Dansyl Chloride
    Aydogmus, Zeynep
    Sari, Ferhat
    Ulu, Sevgi Tatar
    [J]. JOURNAL OF FLUORESCENCE, 2012, 22 (02) : 549 - 556
  • [7] Beckett AH, 2005, PRACTICAL PHARM CHEM, V1, P275
  • [8] STABILITY PROFILE DEVELOPMENT USING SIMULTANEOUS ESTIMATION METHOD FOR FIXED DOSED COMBINATION OF ALISKIREN AND AMLODIPINE BY HPLC
    Choudhari, Snadhya
    Pishawikar, Sachin A.
    Killedar, Suersh G.
    More, Harinath N.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2018, 9 (06): : 2418 - 2423
  • [9] Steady-state and synchronous spectrofluorimetric methods for simultaneous determination of aliskiren hemifumarate and amlodipine besylate in dosage forms
    Ebeid, Walid M.
    Elkady, Ehab F.
    El-Zaher, Asmaa A.
    El-Bagary, Ramzia I.
    Patonay, Gabor
    [J]. LUMINESCENCE, 2014, 29 (07) : 878 - 883
  • [10] Determination of Aliskiren Hemifumarate and Amlodipine Besylate in their Combined Dosage form by Different Spectrophotometric Methods
    Elghobashy, Mohamed Refaat
    Nashat, Nancy Wahid
    Abbas, Samah Sayed
    Moustafa, Azza Aziz
    [J]. CURRENT PHARMACEUTICAL ANALYSIS, 2016, 12 (04) : 391 - 398